Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs

References

• Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086–97
   PubMed Web of Science ®Google Scholar
• Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 2001;17:493–503
   PubMed Web of Science ®Google Scholar
• Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160–84
   PubMed Web of Science ®Google Scholar
• Benson MD. Leptomeningeal amyloid and variant transthyretins. Am J Pathol 1996;148:351–4
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e120
   PubMed Web of Science ®Google Scholar
• Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181–6
   PubMed Web of Science ®Google Scholar
• Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, et al. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997;50:161–81
   PubMedGoogle Scholar
• Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007;274:1637–50
   PubMed Web of Science ®Google Scholar
• Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996;35:6470–82
   PubMed Web of Science ®Google Scholar
• Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 2012;19 Suppl 1:78–80
   PubMedGoogle Scholar
• Ando Y, Ueda M. Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 2012;19:2312–23
   PubMed Web of Science ®Google Scholar
• Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005;352:2356
   PubMed Web of Science ®Google Scholar
• Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007;13:215–18
   PubMed Web of Science ®Google Scholar
• Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, Nanjo H, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006;6:2512–15
   PubMed Web of Science ®Google Scholar
• Llado L, Baliellas C, Casasnovas C, Ferrer I, Fabregat J, Ramos E, Castellote J, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010;16:1386–92
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260:2802–14
   PubMed Web of Science ®Google Scholar
• Illumina I. Gene expression microarray data quality control. Available at: res.illumina.com/documents/products/technotes/technote_gene_expression_data_quality_control.pdf 2010
   Google Scholar
• Hotelling H. The generalization of Student’s ratio. Ann Math Stat 1992;2:360–78
   Google Scholar
• Lee HK, Braynen W, Keshav K, Pavlidis P. ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 2005;6:269
   PubMed Web of Science ®Google Scholar
• Suaud L, Miller K, Alvey L, Yan W, Robay A, Kebler C, Kreindler JL, et al. ERp29 regulates DeltaF508 and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) trafficking to the plasma membrane in cystic fibrosis (CF) and non-CF epithelial cells. J Biol Chem 2011;286:21239–53
   PubMedGoogle Scholar
• Brychzy A, Rein T, Winklhofer KF, Hartl FU, Young JC, Obermann WM. Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system. EMBO J 2003;22:3613–23
   PubMedGoogle Scholar
• Vainberg IE, Lewis SA, Rommelaere H, Ampe C, Vandekerckhove J, Klein HL, Cowan NJ. Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 1998;93:863–73
   PubMed Web of Science ®Google Scholar
• Bush KT, Hendrickson BA, Nigam SK. Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. Biochem J 1994;303:705–8
   PubMedGoogle Scholar
• Gothel SF, Marahiel MA. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999;55:423–36
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Li H, Zhang W, Wu D, Mi H. The mouse FKBP23 binds to BiP in ER and the binding of C-terminal domain is interrelated with Ca2+ concentration. FEBS Lett 2004;559:57–60
   PubMedGoogle Scholar
• Gao Y, Thomas JO, Chow RL, Lee GH, Cowan NJ. A cytoplasmic chaperonin that catalyzes beta-actin folding. Cell 1992;69:1043–50
   PubMed Web of Science ®Google Scholar
• Sternlicht H, Farr GW, Sternlicht ML, Driscoll JK, Willison K, Yaffe MB. The t-complex polypeptide 1 complex is a chaperonin for tubulin and actin in vivo. Proc Natl Acad Sci U S A 1993;90:9422–6
   PubMed Web of Science ®Google Scholar
• Mkrtchian S, Sandalova T. ERp29, an unusual redox-inactive member of the thioredoxin family. Antioxid Redox Signal 2006;8:325–37
   PubMed Web of Science ®Google Scholar
• Sousa MM, do Amaral JB, Guimaraes A, Saraiva MJ. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J 2005;19:124–6
   PubMedGoogle Scholar
• Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR. Why are some amyloidoses systemic? Does hepatic “chaperoning at a distance” prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 2012;26:2283–93
   PubMed Web of Science ®Google Scholar
• Gomes RA, Franco C, Da Costa G, Planchon S, Renaut J, Ribeiro RM, Pinto F, et al. The proteome response to amyloid protein expression in vivo. PLoS One 2012;7:e50123
   PubMedGoogle Scholar
• Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Palladini G, Merlini G, Mauri P. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res 2013;12:5642–55
   PubMed Web of Science ®Google Scholar
• Magalhaes J, Santos SD, Saraiva MJ. alphaB-crystallin (HspB5) in familial amyloidotic polyneuropathy. Int J Exp Pathol 2010;91:515–21
   PubMedGoogle Scholar
• Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Theberge R, Connors LH, et al. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008;7:1570–83
   PubMed Web of Science ®Google Scholar
• Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE, Warrington JA. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 2004;5:88
   PubMed Web of Science ®Google Scholar